完整後設資料紀錄
DC 欄位語言
dc.contributor.authorWu, Szu-Yuanen_US
dc.contributor.authorChou, Hsiao-Yingen_US
dc.contributor.authorYuh, Chiou-Hwaen_US
dc.contributor.authorMekuria, Shewaye Lakewen_US
dc.contributor.authorKao, Yu-Chihen_US
dc.contributor.authorTsai, Hsieh-Chihen_US
dc.date.accessioned2018-08-21T05:53:22Z-
dc.date.available2018-08-21T05:53:22Z-
dc.date.issued2018-02-01en_US
dc.identifier.issn2198-3844en_US
dc.identifier.urihttp://dx.doi.org/10.1002/advs.201700339en_US
dc.identifier.urihttp://hdl.handle.net/11536/144604-
dc.description.abstractCombination of chemotherapy and radiotherapy is used to enhance local drug delivery while reducing off-target tissue effects. Anticancer drug doxorubicin (DOX) is loaded into L-cysteine modified G4.5 dendrimer (GC/DOX) and released at different pH values in the presence and absence of gamma-radiation. Presence of gamma-radiation significantly improves DOX release from the GC/DOX under acidic pH conditions, suggesting that GC dendrimer is a radiation-sensitive drug delivery system. GC/DOX is further evaluated by determining cytotoxicity in uterine cervical carcinoma HeLa cells. GC/DOX shows high affinity for cancer cells and effective drug release following an external stimulus (radiation exposure), whereas an in vivo zebrafish study confirms that l-cysteine acts as a radiosensitizer. GC/DOX treatment combined with radiotherapy synergistically and successfully inhibits cancer cell growth.en_US
dc.language.isoen_USen_US
dc.subjectcombination therapiesen_US
dc.subjectdendrimersen_US
dc.subjectdoxorubicinen_US
dc.subjectHeLa cellsen_US
dc.subjectzebrafishen_US
dc.titleRadiation-Sensitive Dendrimer-Based Drug Delivery Systemen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/advs.201700339en_US
dc.identifier.journalADVANCED SCIENCEen_US
dc.citation.volume5en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000426200000020en_US
顯示於類別:期刊論文